Mineral And Bone Disorder Treatment Market Key Driver 2024

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Mineral And Bone Disorder Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $4.34 billion In 2028 At A CAGR Of 7.1% :

The mineral and bone disorder treatment market size has grown strongly in recent years. It will grow from $3.06 billion in 2023 to $3.3 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to chronic kidney disease, aging population, rising awareness of mineral and bone disorders, increased availability of mineral and bone disorder treatments, rising disposable income levels.

The mineral and bone disorder treatment market size is expected to see strong growth in the next few years. It will grow to $4.34 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to rising demand for quality of life treatments, growing demand for personalized medicine, government spending on healthcare, rising awareness of the importance of early diagnosis. Major trends in the forecast period include advancements in medical research, pharmaceutical developments, digital health, biologic therapies, telehealth and remote monitoring.

Request A Sample Of This Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12956&type=smp

Mineral And Bone Disorder Treatment Market Major Segments
The mineral and bone disorder treatment market covered in this report is segmented -

1) By Treatment: Diet; Nutrition; Medication; Supplements; Dialysis
2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
3) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users

Key Driver - Growing Elderly Population Boosts Mineral And Bone Disorder Treatment Market

The increased elderly population is expected to boost the growth of the mineral and bone disorder treatment market going forward. The elderly population is a demographic group defined as individuals who are 65 years old or older. Elderly people experience muscle and bone mass loss, leading to weakness and reduced strength. Mineral and bone treatment can help prevent age-related changes in muscles, bones and joints, strengthen bones and delay the pace of bone loss. For instance, according to a report published by the World Health Organization (WHO), a Switzerland-based intergovernmental organization, by 2030, the number of people aged 60 years or older is expected to increase from 1 billion in 2020 to 1.4 billion and 2.1 billion by 2050. The number of people aged 80 years or older is projected to be three times from 143 million in 2020 to 426 million in 2050. Therefore, the increased elderly population is driving the growth of the mineral and bone disorder treatment market.

Customise This Report As Per Your Requirements -
https://www.thebusinessresearchcompany.com/Customise?id=12956&type=smp

Prominent Trend - Major Companies Focus On New Product Development To Gain A Competitive Edge

Major companies operating in the mineral and bone disorder treatment market are focusing on developing new products and getting them approved to strengthen their position in the market. Drug approval for mineral and bone is increasing due to the aging population and the increasing prevalence of chronic kidney diseases such as TYMLOS (abaloparatide), which contains the active drug abaloparatide, which is a synthetic (lab-made) form of the human parathyroid hormone. For instance, in December 2022, Radius Health Inc., a US-based biopharmaceutical company, received the approval for TYMLOS (abaloparatide), a parathyroid hormone-related peptide [PTHrP(1-34)] analog for the treatment to increase bone density in men with osteoporosis at high risk of fracture. It works as an anabolic agent for the bone by selectively activating the parathyroid hormone 1 receptor (PTH1R) expressed in osteoblasts and osteocytes, leading to increased bone formation and density.

Mineral And Bone Disorder Treatment Market Players
Major players in the mineral and bone disorder treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Co. Ltd., Eli Lilly And Company, Amgen Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., Mylan N.V., Daiichi Sankyo Company Limited, Servier Laboratories Pty Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Zydus Cadila Healthcare Ltd., Alembic Pharmaceuticals Limited, Ajanta Pharma Ltd., Abiogen Pharma Spa, Melinta Therapeutics Inc., Intas Pharmaceuticals Ltd., Radius Health Inc., EffRx Pharmaceuticals SA.

View The Full Report Here -
https://www.thebusinessresearchcompany.com/report/mineral-and-bone-disorder-treatment-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the mineral and bone disorder treatment market in 2023. The regions covered in mineral and bone disorder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Mineral And Bone Disorder Treatment Market Report Structure
3. Mineral And Bone Disorder Treatment Market Trends And Strategies
4. Mineral And Bone Disorder Treatment Market - Macro Economic Scenario
5. Mineral And Bone Disorder Treatment Market Size And Growth
…..
27. Mineral And Bone Disorder Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.